Analysts are optimistic about Verve Therapeutics, predicting...

Analysts are optimistic about Verve Therapeutics, predicting reduced losses this year, indicating a move towards profitability. Despite expected slower revenue growth, it's still anticipated to outpace the industry. However, concerns like dilutive stock issuance over the past year persist.